Impilo
Investment Details
Investor Type
Private Equity
Asset Class Focus
Private Equity, Venture Capital
Stage Focus
Early Stage, Growth, Late Stage, Buyout
Geographical Focus
United Kingdom, Germany, France, Italy, Denmark, Switzerland, Spain, Austria, Netherlands, Hungary, Sweden, Belgium, Norway, Finland, Poland, Czech Republic, Slovakia, Romania, Bulgaria, Iceland
Industries Focus
- Healthcare Services
- Pharmaceuticals
- Medical Devices
- Diagnostics
- Biotechnology
- Medical Research
- Consumer Health
- Medical Equipment
- Medical Technology
- Health Insurance
- Healthcare IT
- Healthcare Logistics
- Healthcare Consulting
- Healthcare Education
- Preventive Health Services
Investment Size:
50,000,000 to 200,000,000 USD
Investor Details Founded: 2017
Impilo is a Nordic investment company dedicated to long-term investments in sustainable healthcare companies operating in pharmaceuticals, medical technology, healthcare services, and other health-related sectors. Their investment strategy emphasizes positive and sustainable development within the societies and markets where their portfolio companies operate, aiming to enhance the quality of healthcare and improve health outcomes.
The company targets private majority investments in companies with enterprise values ranging from EUR 50 million to EUR 200 million, though minority and public investments are also considered if they provide relevant governance rights. Impilo seeks companies with the potential to double operating profit over five years and outgrow their respective markets. Their investment approach is guided by the Impilo Health Diamond, focusing on scalable solutions, increased healthcare capacity, cost reduction, and preventive care.
Since its inception in 2017, Impilo has raised approximately SEK 10 billion in capital from leading Nordic and international investors. Their portfolio includes companies such as Decon, a developer of power-assisted solutions for wheelchairs, and Avia Pharma, a distributor of OTC and prescription pharmaceuticals in the Nordics and Germany. Impilo's commitment to sustainability is reflected in their Responsible Investment and Ownership Policy, which integrates sustainability principles throughout the investment process and ownership cycle.
Requirements
- Positive health impact
- Sustainable development
- Potential to double operating profit over 5 years
- Outgrowth of relevant markets
- Scalable solutions
- Increased healthcare capacity
- Cost reduction
- Preventive care
Contact
[Official Website Hidden]
[LinkedIn Profile Hidden]
[HQ Location Hidden]
[Email Hidden]
[Contact Number Hidden]
Portfolio Companies
- Decon
- Avia Pharma
Claim this Investor
Are you an official representative of Impilo?
Claim this investor to update information, manage your profile, and get a verified seal.
Claim